Construction of Promoter-Ribosome Binding Site Library for Manipulating Gene Expression in the Hyperthermophilic Archaeon Thermococcus kodakarensis
ACS Synthetic Biology · 2025
DOI: 10.1021/acssynbio.5c00086 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, 2025. Verfasst von Cong Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China. Hauptthemen laut MEDLINE: Thermococcus, Promoter Regions, Genetic, Ribosomes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Shanghai Jiao Tong University, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
ORCID-Profile: Jun Xu
Förderung
- Shanghai Jiao Tong University
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Li, C., & Xu, J. (2025). Construction of Promoter-Ribosome Binding Site Library for Manipulating Gene Expression in the Hyperthermophilic Archaeon Thermococcus kodakarensis. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.5c00086
Vancouver
Li C, Xu J. Construction of Promoter-Ribosome Binding Site Library for Manipulating Gene Expression in the Hyperthermophilic Archaeon Thermococcus kodakarensis. ACS Synthetic Biology. 2025. doi:10.1021/acssynbio.5c00086
BibTeX
@article{Li2025,
author = {Li, Cong and Xu, Jun},
title = {Construction of Promoter-Ribosome Binding Site Library for Manipulating Gene Expression in the Hyperthermophilic Archaeon Thermococcus kodakarensis},
journal = {ACS Synthetic Biology},
year = {2025},
doi = {10.1021/acssynbio.5c00086}
}
EUVIMED